Self-monitoring of blood glucose in diabetes: from evidence to clinical reality in Central and Eastern Europe--recommendations from the international Central-Eastern European expert group.

Abstract:

:Self-monitoring of blood glucose (SMBG) is universally considered to be an integral part of type 1 diabetes management and crucial for optimizing the safety and efficacy of complex insulin regimens. This extends to type 2 diabetes patients on intensive insulin therapy, and there is also a growing body of evidence suggesting that structured SMBG is beneficial for all type 2 diabetes patients, regardless of therapy. However, access to SMBG can be limited in many countries in Central and Eastern Europe. A consensus group of diabetes experts from 10 countries in this region (with overlapping historical, political, and social environments)--Bulgaria, Croatia, Czech Republic, Hungary, Poland, Romania, Serbia, Slovakia, Slovenia, and Ukraine--was formed to discuss the role of SMBG across the spectrum of patients with diabetes. The group considered SMBG to be an essential tool that should be accessible to all patients with diabetes, including those with non-insulin-treated type 2 diabetes. The current article summarizes the evidence put forward by the consensus group and provides their recommendations for the appropriate use of SMBG as part of individualized patient management. The ultimate goal of these evidence-based recommendations is to help patients and providers in Central and Eastern Europe to make optimal use of SMBG in order to maximize the efficacy and safety of glucose-lowering therapies, to prevent complications, and to empower the patient to play a more active role in the management of their diabetes.

journal_name

Diabetes Technol Ther

authors

Czupryniak L,Barkai L,Bolgarska S,Bronisz A,Broz J,Cypryk K,Honka M,Janez A,Krnic M,Lalic N,Martinka E,Rahelic D,Roman G,Tankova T,Várkonyi T,Wolnik B,Zherdova N

doi

10.1089/dia.2013.0302

subject

Has Abstract

pub_date

2014-07-01 00:00:00

pages

460-75

issue

7

eissn

1520-9156

issn

1557-8593

journal_volume

16

pub_type

杂志文章,评审
  • Feasibility Study of a Hybrid Closed-Loop System with Automated Insulin Correction Boluses.

    abstract:: Background: The Medtronic MiniMed™ 670G system adjusts basal insulin delivery in response to continuous glucose monitoring levels and is already in use in clinical practice. We tested the home-based feasibility of the new MiniMed advanced hybrid closed-loop (AHCL) system, ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2020.0448

    authors: Nimri R,Grosman B,Roy A,Nir J,Fisch Shvalb N,Kurtz N,Loewenthal N,Gillon-Keren M,Muller I,Atlas E,Phillip M

    更新日期:2020-12-08 00:00:00

  • RETRACTED: No deleterious effect of lockdown due to COVID-19 pandemic on glycaemic control, measured by glucose monitoring, in adults with type 1 diabetes.

    abstract::The Editor of Diabetes Technology & Therapeutics is officially retracting the article entitled, "No Deleterious Effect of Lockdown Due to COVID-19 Pandemic on Glycaemic Control, Measured by Glucose Monitoring, in Adults with Type 1 Diabetes," by Beato-Vibora PI. Diabetes Technol Ther 2020; epub DOI: 10.1089/dia.2020.0...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,收录出版

    doi:10.1089/dia.2020.0184

    authors: Beato-Víbora PI

    更新日期:2020-05-12 00:00:00

  • Factors Affecting Recruitment of Participants for Studies of Diabetes Technology in Newly Diagnosed Youth with Type 1 Diabetes: A Qualitative Focus Group Study with Parents and Children.

    abstract:BACKGROUND:Relatively little is known about parents' or children's attitudes toward recruitment for, and participation in, studies of new diabetes technologies immediately after diagnosis. This study investigated factors affecting recruitment of participants for studies in newly diagnosed youth with type 1 diabetes. M...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2016.0157

    authors: Farrington C,Allen J,Tauschmann M,Randell T,Trevelyan N,Hovorka R

    更新日期:2016-09-01 00:00:00

  • Validation of physical activity monitors in individuals with diabetes: energy expenditure estimation by the multisensor SenseWear Armband Pro3 and the step counter Omron HJ-720 against indirect calorimetry during walking.

    abstract:BACKGROUND:The purpose of this study is to test the agreement between energy expenditure estimate of the SenseWear(®) Armband Pro3 (SWA) (BodyMedia, Pittsburgh, PA) and the Omron HJ-720 (Omron Healthcare, Kyoto, Japan) step counter with indirect calorimetry (IC) as a gold standard in older individuals with type 1 and t...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2012.0235

    authors: Machač S,Procházka M,Radvanský J,Slabý K

    更新日期:2013-05-01 00:00:00

  • Differences in exhaled gas profiles between patients with type 2 diabetes and healthy controls.

    abstract:AIMS:Recent advances in analytical technology allow the detection of several hundred volatile organic compounds (VOCs) in human exhaled air, many of which reflect unidentified endogenous pathways. This study was performed to determine whether a breath gas analysis using proton transfer reaction-mass spectrometry (PTR-M...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2009.0181

    authors: Greiter MB,Keck L,Siegmund T,Hoeschen C,Oeh U,Paretzke HG

    更新日期:2010-06-01 00:00:00

  • Where Do We Stand with Closed-Loop Systems and Their Challenges?

    abstract::Treatments for type 1 diabetes have advanced significantly over recent years. There are now multiple hybrid closed-loop systems commercially available and additional systems are in development. Challenges remain, however. This review outlines the recent advances in closed-loop systems and outlines the remaining challe...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2019.0469

    authors: Jackson M,Castle JR

    更新日期:2020-07-01 00:00:00

  • Basal plus basal-bolus approach in type 2 diabetes.

    abstract::Type 2 diabetes is characterized by insulin resistance and progressive β-cell deterioration. As β-cell function declines, most patients with type 2 diabetes treated with oral agents, in monotherapy or combination, will require insulin therapy. Addition of basal insulin (glargine, detemir, or NPH/neutral protamine lisp...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1089/dia.2011.0001

    authors: Ampudia-Blasco FJ,Rossetti P,Ascaso JF

    更新日期:2011-06-01 00:00:00

  • Safety Evaluation of the MiniMed 670G System in Children 7-13 Years of Age with Type 1 Diabetes.

    abstract:OBJECTIVE:To evaluate the safety of in-home use of the MiniMed™ 670G system with SmartGuard™ technology in children with type 1 diabetes (T1D). METHODS:Participants (N = 105, ages 7-13 years, mean age 10.8 ± 1.8 years) were enrolled at nine centers (eight in the United States and one in Israel) and completed a 2-week ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2018.0264

    authors: Forlenza GP,Pinhas-Hamiel O,Liljenquist DR,Shulman DI,Bailey TS,Bode BW,Wood MA,Buckingham BA,Kaiserman KB,Shin J,Huang S,Lee SW,Kaufman FR

    更新日期:2019-01-01 00:00:00

  • Continuous glucose monitoring by means of the microdialysis technique: underlying fundamental aspects.

    abstract::The microdialysis technique allows extraction of substances (e.g., glucose) from fluids in the human body for quantitative measurements ex vivo. The microdialysis catheter can be inserted in many different tissues; for continuous glucose monitoring it is most often implanted in the subcutaneous fat tissue in the abdom...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1089/152091503322250578

    authors: Heinemann L,Glucose Monitoring Study Group.

    更新日期:2003-01-01 00:00:00

  • Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 1 Diabetes Also Using Insulin Glargine-SORELLA 1 Study.

    abstract:BACKGROUND:SAR342434 is a biosimilar follow-on of insulin lispro-Humalog®. This study aimed to show similar efficacy, safety, and immunogenicity of SAR342434 (SAR-Lis) versus insulin lispro-Humalog (Ly-Lis) in adult patients with type 1 diabetes (T1DM) treated with multiple daily injections while using basal insulin gl...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1089/dia.2017.0117

    authors: Garg SK,Wernicke-Panten K,Rojeski M,Pierre S,Kirchhein Y,Jedynasty K

    更新日期:2017-09-01 00:00:00

  • Limitations of the HOMA-B score for assessment of beta-cell functionality in interventional trials-results from the PIOglim study.

    abstract:BACKGROUND:Drugs with unspecific stimulating effects on beta-cell secretion increase the homeostasis model assessment (HOMA)-B score, indicating improved beta-cell "function." We investigated whether the beta-cell protection provided by adding pioglitazone (PIO) to glimepiride (GLIM) in comparison to up-titrating the G...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1089/dia.2010.0019

    authors: Pfützner A,Derwahl M,Jacob S,Hohberg C,Blümner E,Lehmann U,Fuchs W,Forst T

    更新日期:2010-08-01 00:00:00

  • The Value of Automated Diabetic Retinopathy Screening with the EyeArt System: A Study of More Than 100,000 Consecutive Encounters from People with Diabetes.

    abstract:: Background: Current manual diabetic retinopathy (DR) screening using eye care experts cannot scale to screen the growing population of diabetes patients who are at risk for vision loss. EyeArt system is an automated, cloud-based artificial intelligence (AI) eye screening t...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2019.0164

    authors: Bhaskaranand M,Ramachandra C,Bhat S,Cuadros J,Nittala MG,Sadda SR,Solanki K

    更新日期:2019-11-01 00:00:00

  • Validation of the SoloSTAR insulin pen.

    abstract:BACKGROUND:This study was designed to validate the use of SoloSTAR (sanofi-aventis Deutschland GmbH, Frankfurt, Germany), a new disposable pen developed for use with insulin glargine by patients with type 1 or type 2 diabetes. METHODS:This single-center, open-label, single-arm, sequential trial enrolled subjects with ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1089/dia.2008.0079

    authors: Schwartz S,Vlajnic A

    更新日期:2008-10-01 00:00:00

  • Automatic learning algorithm for the MD-logic artificial pancreas system.

    abstract:BACKGROUND:Applying real-time learning into an artificial pancreas system could effectively track the unpredictable behavior of glucose-insulin dynamics and adjust insulin treatment accordingly. We describe a novel learning algorithm and its performance when integrated into the MD-Logic Artificial Pancreas (MDLAP) syst...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2010.0216

    authors: Miller S,Nimri R,Atlas E,Grunberg EA,Phillip M

    更新日期:2011-10-01 00:00:00

  • Increased Time in Range and Fewer Missed Bolus Injections After Introduction of a Smart Connected Insulin Pen.

    abstract:: Background: This observational study investigated whether the connected NovoPen® 6 could influence insulin regimen management and glycemic control in people with type 1 diabetes (T1D) using a basal-bolus insulin regimen and continuous glucose monitoring in a real-world set...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2019.0411

    authors: Adolfsson P,Hartvig NV,Kaas A,Møller JB,Hellman J

    更新日期:2020-10-01 00:00:00

  • Home blood glucose prediction: validation, safety, and efficacy testing in clinical diabetes.

    abstract:BACKGROUND:Patients with diabetes do daily self-monitoring of blood glucose (SMBG). For such patients, we devised an engine that predicts not only the expected blood glucose level at the next meal but also the pending risks of hypoglycemia. The purpose of this study was to validate the predictions and provide evidence ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2005.7.487

    authors: Albisser AM,Sakkal S,Wright C

    更新日期:2005-06-01 00:00:00

  • Development of a Collaborative Algorithm for the Management of Type 2 Diabetes during Ramadan: An Anchor on Empowerment.

    abstract::Empowerment plays significant roles in the complex management of type 2 diabetes. International guidelines have provided recommendations on management of Muslims who fast during Ramadan. However, there remains a lack of patient-centered epistemic tool to empower healthcare providers and patients in managing diabetes d...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1089/dia.2018.0159

    authors: Lum ZK,See Toh WY,Lim SM,Rusli KDB,Abdul Shakoor SAKK,Tsou KYK,Chew DEK,Dalan R,Kwek SC,Othman N,Lian JX,Lee JY

    更新日期:2018-10-01 00:00:00

  • Obesity and diabetes: newer concepts in imaging.

    abstract::Quantifying body fat is currently an area of active research. Recent studies have shown that the quantity and location of fat in different compartments have varying clinical significance. This information can now be obtained from computed tomography (CT) or magnetic resonance (MR), and it can inform clinical decision ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1089/dia.2013.0039

    authors: Garg K,Chang S,Scherzinger A

    更新日期:2013-05-01 00:00:00

  • Role of continuous subcutaneous insulin infusion in patients with recalcitrant diabetes in South India.

    abstract:BACKGROUND:We aimed to assess the effect of continuous subcutaneous insulin infusion (CSII) therapy in patients with "recalcitrant diabetes" whose glycemia had not been controlled adequately with multiple daily injections of insulin or insulin plus oral hypoglycemic agents. PATIENTS AND METHODS:We retrospectively anal...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2009.0066

    authors: Sudhakaran C,Anjana RM,Rao K,Unnikrishnan R 1st,Suresh T,Mohan V

    更新日期:2009-11-01 00:00:00

  • Venous, Arterialized-Venous, or Capillary Glucose Reference Measurements for the Accuracy Assessment of a Continuous Glucose Monitoring System.

    abstract:BACKGROUND:Different reference methods are used for the accuracy assessment of continuous glucose monitoring (CGM) systems. The effect of using venous, arterialized-venous, or capillary reference measurements on CGM accuracy is unclear. METHODS:We evaluated 21 individuals with type 1 diabetes using a capillary calibra...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1089/dia.2017.0189

    authors: Kropff J,van Steen SC,deGraaff P,Chan MW,van Amstel RBE,DeVries JH

    更新日期:2017-11-01 00:00:00

  • Resistance to Data Loss of Glycemic Variability Measurements in Long-Term Continuous Glucose Monitoring.

    abstract:: Background: Continuous glucose monitoring (CGM) is a method of estimating blood glucose values from those recorded in the interstitial fluid. Because increasingly longer CGM measurements are possible, errors and data loss become more and more likely and potentially more da...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2018.0247

    authors: Kucharski P,Pagacz K,Szadkowska A,Młynarski W,Romanowski A,Fendler W

    更新日期:2018-12-01 00:00:00

  • Randomized Evaluation of Glycemic Control in the Medical Intensive Care Unit Using Real-Time Continuous Glucose Monitoring (REGIMEN Trial).

    abstract:BACKGROUND AND OBJECTIVE:Hyperglycemia occurs commonly in patients admitted to medical intensive care units (MICUs). Whether real-time (RT) continuous glucose monitoring (CGM) improves glycemic control and variability and reduces hypoglycemia in severely ill MICU patients with an Acute Physiology and Chronic Health Eva...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1089/dia.2015.0151

    authors: De Block CE,Gios J,Verheyen N,Manuel-y-Keenoy B,Rogiers P,Jorens PG,Scuffi C,Van Gaal LF

    更新日期:2015-12-01 00:00:00

  • Management of patients with diabetes through information technology: tools for monitoring and control of the patients' metabolic behavior.

    abstract:BACKGROUND:The junction of telemedicine home monitoring with multifaceted disease management programs seems nowadays a promising direction to combine the need for an intensive approach to deal with diabetes and the pressure to contain the costs of the interventions. Several projects in the European Union and the United...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2004.6.567

    authors: Bellazzi R,Arcelloni M,Ferrari P,Decata P,Hernando ME,García A,Gazzaruso C,Gómez EJ,Larizza C,Fratino P,Stefanelli M

    更新日期:2004-10-01 00:00:00

  • Efficacy and safety performance of the Innovo insulin doser.

    abstract::Innovo (Novo Nordisk A/S, Hillerød, Denmark) is a new insulin injection system that offers built-in memory and a large, clear display to provide patients with more control during insulin injections. The aim of this trial was to compare the efficacy and safety of Innovo and NovoPen 3 (Novo Nordisk A/S) in patients expe...

    journal_title:Diabetes technology & therapeutics

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1089/152091504322783413

    authors: Valk NK,Cerny G,Sieber J,Lytzen L,Berg B

    更新日期:2004-02-01 00:00:00

  • Diabetes registries: where we are and where are we headed?

    abstract::Disease registries are a searchable list of all patients with a particular chronic condition that often interface with an electronic medical record. The well-designed registry links all members of the patient's health team and provides key information for patients and physicians. The critical impact of a registry is t...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2008.0057

    authors: Khan L,Mincemoyer S,Gabbay RA

    更新日期:2009-04-01 00:00:00

  • Oral insulin product hexyl-insulin monoconjugate 2 (HIM2) in type 1 diabetes mellitus: the glucose stabilization effects of HIM2.

    abstract::This study was designed to determine plasma glucose and insulin levels after administration of three escalating doses of the oral insulin product hexyl-insulin monoconjugate 2 (HIM2) in fasting, insulin-deprived adult patients with type 1 diabetes. The study was also designed to assess the safety of the product. Sixte...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/152091502760306544

    authors: Clement S,Still JG,Kosutic G,McAllister RG

    更新日期:2002-01-01 00:00:00

  • Using multiple measures of glycemia to support individualized diabetes management: recommendations for clinicians, patients, and payers.

    abstract::By the year 2030, the diabetes pandemic will likely affect more than 10% of the world's population. The personal, public health, and economic crises implicit in this trend call for decisive action. Yet, escalating dilemmas thwart full realization of current therapies. First, controversial studies, such as the Action t...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1089/dia.2012.0132

    authors: Hirsch IB,Amiel SA,Blumer IR,Bode BW,Edelman SV,Seley JJ,Verderese CA,Kilpatrick ES

    更新日期:2012-11-01 00:00:00

  • Continuous Glucose Monitoring, Glycemic Variability, and Excessive Fetal Growth in Pregnancies Complicated by Type 1 Diabetes.

    abstract:BACKGROUND:To examine trimester-specific associations among glycemic variability, fetal growth, and birthweight in pregnancies with type 1 diabetes mellitus (Type 1 DM). METHODS:In this retrospective cohort study of 41 pregnant women with Type 1 DM, we used continuous glucose monitoring (CGM) data to calculate glycemi...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2017.0443

    authors: Mulla BM,Noor N,James-Todd T,Isganaitis E,Takoudes TC,Curran A,Warren CE,O'Brien KE,Brown FM

    更新日期:2018-06-01 00:00:00

  • Perioperative Characteristics of the Accuracy of Subcutaneous Continuous Glucose Monitoring: Pilot Study in Neurosurgery and Cardiac Surgery.

    abstract:BACKGROUND:The aim of this study was to elucidate the characteristics of accuracy of subcutaneous continuous glucose monitoring (SCGM) in the perioperative period for neurosurgical and cardiac surgery patients. METHODS:Forty-five subjects, including healthy volunteers (n = 15), neurosurgical patients (n = 15), and car...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2018.0140

    authors: Sugiyama Y,Wakabayashi R,Urasawa M,Maruyama Y,Shimizu S,Kawamata M

    更新日期:2018-10-01 00:00:00

  • Inaccurate Glucose Sensor Values After Hydroxyurea Administration.

    abstract:: Objective: To assess the degree, duration, mean absolute relative difference (MARD), and error analysis of discrepant values per continuous glucose monitoring (CGM) systems after hydroxyurea (HU) administration. Research Design and Methods: ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2020.0490

    authors: Tellez SE,Hornung LN,Courter JD,Abu-El-Haija M,Nathan JD,Lawson SA,Elder DA

    更新日期:2020-12-30 00:00:00